• Our Services

    We offer best-in-class research and consulting services pertaining to the markets of all geographies. Our experienced team of business analysts and consultants has mastered fundamental and advanced market research in diverse industries.

  • Syndicated Research

    Syndicated research is the most cost-effective market research approach, which gives an analytical outlook of the competitive positioning, product positioning, and size estimation of the market at the micro level. Our off-the-shelf reports offer key market insights that industry stakeholders require to base their business strategy on. Our syndicated research services empower our clients to meet diverse market objectives.

  • Customized Research

    we also deliver customized research services to address specific needs of our clients. With a vast pool of adroit analysts who are proficient in market research, we take pride in tailoring our research services to meet our clients’ definite requirements and aid their business growth.

  • Consulting Services

    Businesses, today, need to adapt themselves to the changes that transpire in the market. Staying abreast of the market trends, therefore, becomes imperative for accomplishing business objectives.

  • Our Vision

    To be the most trusted partner in our clients' success endeavors

Showing posts with label Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) Inhibitor Therapeutics - Pipeline Analysis 2018. Show all posts
Showing posts with label Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) Inhibitor Therapeutics - Pipeline Analysis 2018. Show all posts

Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) Inhibitor Therapeutics - Pipeline Analysis , Clinical Trials & Results


Cytotoxic T-lymphocyte antigen-4 (CTLA-4) plays important role in the T-cell regulation at an early stage of naive T-cell activation, primarily in the lymph nodes. CTLA-4 has emerged as an attractive cancer immunotherapy as a part of “immune checkpoint blockade”. CTLA-4 pathway inhibitors enhance T-cell activation and amplify T-cell proliferation. Successful results of immune checkpoint inhibitors in cancer immunotherapy has led to the development of many new agents and strategies, including combination for the treatment of various cancers.
Despite of many advancements in the development of anti-cancer therapies, cancer is still one of the major causes of deaths, globally. Combination therapies are proving to be more efficient than monotherapy for the treatment of cancer. Studies have demonstrated that concurrent PD-1 and CTLA-4 blockade have shown positive results in patients with advanced melanoma. This provides huge opportunities for development of better combinatorial immunotherapeutic therapies for checkpoint blockade with molecular targeted therapies, angiogenesis inhibition and novel vaccines.
Request to Get the Sample Pages at:  
Agenus Inc. is in the process of developing AGEN1884 as a monoclonal antibody which acts as a CTLA-4 inhibitor for the treatment of non-small cell lung cancer. It is also being studied in combination with pembrolizumab, for the treatment of cancer. Some of the other companies having pipeline of CTLA-4 inhibitor include AstraZeneca PLC, ​ImmunOs Therapeutics AG, Tikcro Technologies Ltd.

Share:

Profile

Popular Posts

APSense

Labels

Linkedin Profile

APSense

Business Network

Recent Posts

Research Pages